What Is TB-500?
TB-500 is a synthetic 43-amino-acid peptide that replicates the active region of Thymosin Beta-4 (Tβ4), a naturally occurring 43-amino-acid protein found in virtually every human cell. Thymosin Beta-4 is one of the most abundant intracellular proteins in the body, with highest concentrations in platelets, wound fluid, and developing tissues.
TB-500 was developed to capture the regenerative properties of the active region of Tβ4 in a more practical, shelf-stable format for research applications.
Mechanism of Action: Actin Polymerization
TB-500's primary mechanism is the regulation of actin, a protein that forms the structural framework (cytoskeleton) of every cell. By sequestering G-actin monomers, TB-500 promotes the polymerization of actin filaments — the physical scaffolding cells need to move, divide, and migrate.
This actin regulation enables three key therapeutic effects: cell migration (repair cells travel to injury sites), angiogenesis (new blood vessel formation via endothelial cell migration), and reduced inflammation (modulation of IL-6, TNF-α, and NF-κB).
Dosing Protocol: Loading and Maintenance
Loading phase: 2-5 mg SubQ twice weekly for 4-6 weeks. The loading phase saturates tissues and initiates the repair cascade.
Maintenance phase: 2 mg SubQ once weekly for 4-8 weeks. Maintains repair signaling after initial loading.
Injection site: Unlike BPC-157, TB-500 works systemically — inject SubQ anywhere (abdomen, thigh, arm). It does not need to be near the injury.
Reconstitution: 5mg vial + 2mL BAC water = 2.5 mg/mL. For a 2.5mg dose, draw 100 units on a U-100 syringe (full 1mL syringe).
Clinical Evidence and Research
TB-500 has extensive preclinical data in cardiac repair, dermal wound healing, and corneal injury models. In cardiac studies, Tβ4 promoted cardiomyocyte migration and reduced scar formation after myocardial infarction.
Equine research: TB-500 (as Tβ4) has been extensively used and studied in racehorse medicine for tendon and ligament repair, leading to its ban by racing authorities — which indirectly validates its efficacy.
Human clinical trials are limited. Most evidence comes from animal studies and observational clinical use. This is an important limitation to acknowledge.
Safety and Stacking
TB-500 is generally well-tolerated with mild side effects: occasional headache, lethargy during loading phase, and injection site irritation. No LD50 has been established in animal studies.
Stacking: Most commonly stacked with BPC-157 (the "Wolverine Stack"). BPC provides localized VEGF-driven repair while TB-500 provides systemic cell migration — together they address both halves of the healing equation.
⚕️ Medical Disclaimer: This article is for educational purposes only. Consult a qualified healthcare provider before using any peptide.